These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 16519036)

  • 1. Assessing the role of biphasic insulin aspart 30 as an effective and tolerable front-line therapy for type 2 diabetes.
    Garber AJ
    Clin Ther; 2005; 27 Suppl B():S39-41. PubMed ID: 16519036
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus.
    Niskanen L; Jensen LE; Råstam J; Nygaard-Pedersen L; Erichsen K; Vora JP
    Clin Ther; 2004 Apr; 26(4):531-40. PubMed ID: 15189750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus.
    McSorley PT; Bell PM; Jacobsen LV; Kristensen A; Lindholm A
    Clin Ther; 2002 Apr; 24(4):530-9. PubMed ID: 12017398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin aspart: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM; Noble S; Goa KL
    Drugs; 2002; 62(13):1945-81. PubMed ID: 12215068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J; Vexiau P; Cucinotta D; Vaz J; Kawamori R
    Clin Ther; 2005; 27 Suppl B():S75-88. PubMed ID: 16519039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11).
    Hirao K; Arai K; Yamauchi M; Takagi H; Kobayashi M;
    Diabetes Res Clin Pract; 2008 Jan; 79(1):171-6. PubMed ID: 17919762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biphasic insulin aspart 30 for the treatment of type 1 diabetes mellitus.
    Velásquez-Mieyer PA; Neira CP
    Expert Opin Pharmacother; 2008 Sep; 9(13):2377-82. PubMed ID: 18710361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMixstudy.
    Jang HC; Lee SR; Vaz JA
    Diabetes Obes Metab; 2009 Jan; 11(1):20-6. PubMed ID: 18479469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Improvement in glycemic control, cardiovascular risk factors and anthropometric data in type 2 diabetic patients after the switch from biphasic human insulin to biphasic premix analog insulin aspart].
    Gero L; Gyimesi A; Hidvégi T; Jánosi I
    Orv Hetil; 2009 Aug; 150(35):1637-47. PubMed ID: 19692308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
    Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
    Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful management of type IV hypersensitivity reactions to human insulin analogue with injecting mixtures of biphasic insulin aspart and dexamethasone.
    Wen WL; Tsai KB; Lin YH; Hwang SJ; Hsiao PJ; Shin SJ; Hung WW
    J Formos Med Assoc; 2019 Apr; 118(4):843-848. PubMed ID: 30704815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients.
    Boehm BO; Home PD; Behrend C; Kamp NM; Lindholm A
    Diabet Med; 2002 May; 19(5):393-9. PubMed ID: 12027927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biphasic insulin aspart (NovoMix 50)].
    Radermecker RP; Scheen AJ
    Rev Med Liege; 2008 Nov; 63(11):688-92. PubMed ID: 19112996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review.
    Gough SC; Tibaldi J
    Clin Drug Investig; 2007; 27(5):299-324. PubMed ID: 17451279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of exenatide with biphasic insulin aspart 30 on glucose variability in type 2 diabetes: study protocol for a randomized controlled trial.
    Xu S; Liu X; Ming J; Ji Q
    Trials; 2016 Mar; 17():160. PubMed ID: 27009108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes.
    Raja-Khan N; Warehime SS; Gabbay RA
    Vasc Health Risk Manag; 2007; 3(6):919-35. PubMed ID: 18200811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70.
    Ohira M; Endo K; Oyama T; Yamaguchi T; Ban N; Kawana H; Nagayama D; Nagumo A; Saiki A; Murano T; Watanabe H; Miyashita Y; Shirai K
    Metabolism; 2011 Jan; 60(1):78-85. PubMed ID: 20667560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.